Use of Modern Thyroid Tests in Illustrative Ambulatory Patients

552 Using B-type natriuretic peptide (BNP) in ambulatory patients with chronic heart failure and concomitant chronic renal insufficiency

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(03)90357-2 ◽

2003 ◽

Vol 2 (1) ◽

pp. 117-118

Author(s):

M LEE ◽

W TANG ◽

J GIROD ◽

R STARLING ◽

J YOUNG ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Renal Insufficiency ◽

Natriuretic Peptide ◽

Chronic Renal Insufficiency ◽

Ambulatory Patients

Download Full-text

MS2/Cardio: Towards a Multi-Service Medical Software for Cardiology

Methods of Information in Medicine ◽

10.1055/s-0038-1634856 ◽

1992 ◽

Vol 31 (01) ◽

pp. 18-28 ◽

Cited By ~ 2

Author(s):

C. Combi ◽

G. Pozzi ◽

R. Rossi ◽

F. Pinciroli

Keyword(s):

Statistical Processing ◽

Clinical Information ◽

Daily Practice ◽

Management Unit ◽

Record Management ◽

Medical Software ◽

Software Packages ◽

Ambulatory Patients ◽

Patient Database ◽

Individual Program

Abstract:Many clinics are interested to use software packages in daily practice, but lack of integration of such packages seriously limits their scope. In practice this often entails switching between programs and interrupting the run of an individual program. A multi-task approach would not solve this problem as it would not eliminate the need to input the same data many times, as often occurs when using separate packages. The construction of a Multi-Service Medical Software package (MSx2) is described, which was also developed as an example of practical integration of some clinically relevant functions. The package runs on a personal computer in an MS-DOS environment and integrates a time-oriented medical record management unit (TOMRU) for data of ambulatory patients, and a drug information management unit (DIMU) concerning posology, content, effects, and possible interactions. Of the possible database configurations allowed by MSx2, the cardiology patient database (MSx2/C) and hypertensive patient database (MSx2/H) were developed and described here. Clinical information to be included in the configurations was obtained after discussion and consensus of clinical practitioners. MSx2/C was distributed to several hundred clinical centers during computerized courses to train future users. MSx2 can easily transfer patient data to statistical processing packages.

Download Full-text

Platelet Anti-Aggregating Activity and Tolerance of Clopidogrel in Atherosclerotic Patients

Thrombosis and Haemostasis ◽

10.1055/s-0038-1650689 ◽

1996 ◽

Vol 76 (06) ◽

pp. 0939-0943 ◽

Cited By ~ 74

Author(s):

B Boneu ◽

G Destelle ◽

Keyword(s):

Platelet Aggregation ◽

Large Scale ◽

Bleeding Time ◽

Antithrombotic Activity ◽

Ambulatory Patients ◽

Patients At Risk ◽

Set Up ◽

Ischemic Events ◽

Large Scale Clinical Trial ◽

Selection Of

SummaryThe anti-aggregating activity of five rising doses of clopidogrel has been compared to that of ticlopidine in atherosclerotic patients. The aim of this study was to determine the dose of clopidogrel which should be tested in a large scale clinical trial of secondary prevention of ischemic events in patients suffering from vascular manifestations of atherosclerosis [CAPRIE (Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events) trial]. A multicenter study involving 9 haematological laboratories and 29 clinical centers was set up. One hundred and fifty ambulatory patients were randomized into one of the seven following groups: clopidogrel at doses of 10, 25, 50,75 or 100 mg OD, ticlopidine 250 mg BID or placebo. ADP and collagen-induced platelet aggregation tests were performed before starting treatment and after 7 and 28 days. Bleeding time was performed on days 0 and 28. Patients were seen on days 0, 7 and 28 to check the clinical and biological tolerability of the treatment. Clopidogrel exerted a dose-related inhibition of ADP-induced platelet aggregation and bleeding time prolongation. In the presence of ADP (5 \lM) this inhibition ranged between 29% and 44% in comparison to pretreatment values. The bleeding times were prolonged by 1.5 to 1.7 times. These effects were non significantly different from those produced by ticlopidine. The clinical tolerability was good or fair in 97.5% of the patients. No haematological adverse events were recorded. These results allowed the selection of 75 mg once a day to evaluate and compare the antithrombotic activity of clopidogrel to that of aspirin in the CAPRIE trial.

Download Full-text

Evaluation of epidemiological data on effect of therapy with Ipigrix® on motor and sensory functions in ambulatory patients with various diseases ofperipheral nervous system

Medical alphabet ◽

10.33667/2078-5631-2019-1-2(377)-11-14 ◽

2019 ◽

Vol 1 (2) ◽

pp. 11-14

Author(s):

O. S. Levin ◽

O. V. Matvievskaya

Keyword(s):

Nervous System ◽

Observational Study ◽

Peripheral Nervous System ◽

Epidemiological Data ◽

Comprehensive Analysis ◽

Ambulatory Patients ◽

Effect Of Therapy ◽

Sensory Functions

The article contains a comprehensive analysis of the summary epidemiological data obtained during the observational study to assess the effect of therapy with Ipigrix® on the dynamics of motor and sensory functions, as well as the severity of pain in outpatient patients with various diseases of the peripheral nervous system: mononeuropathy, polyneuropathy and polyradiculopathy of various origins.

Download Full-text